The role of rechallenge with targeted therapies in metastatic renal-cell carcinoma

Current Opinion in Urology

Volumn 25, Issue 5, 2015, Pages 402-410

  Oudard, Stéphane ^a,b   Vano, Yann ^a,b  

^a HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

Metastatic renal cell carcinoma; Rechallenge; Targeted therapy; Vascular endothelial growth factor

Indexed keywords

MAMMALIAN TARGET OF RAPAMYCIN; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; SUNITINIB; VASCULOTROPIN; ANGIOGENESIS INHIBITOR; PROTEIN KINASE INHIBITOR;

ALGORITHM; BREAST METASTASIS; CANCER RESISTANCE; CASTRATION RESISTANT PROSTATE CANCER; CLINICAL EFFECTIVENESS; HEALTH CARE QUALITY; HUMAN; KIDNEY METASTASIS; MOLECULARLY TARGETED THERAPY; OVARY CANCER; PRIORITY JOURNAL; RETROSPECTIVE STUDY; REVIEW; SMALL CELL LUNG CANCER; CARCINOMA, RENAL CELL; DRUG ADMINISTRATION; DRUG RESISTANCE; DRUG SUBSTITUTION; ENZYMOLOGY; KIDNEY NEOPLASMS; MORTALITY; PATHOLOGY; SECONDARY; TIME FACTOR; TREATMENT OUTCOME;

ANGIOGENESIS INHIBITORS; CARCINOMA, RENAL CELL; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE, NEOPLASM; DRUG SUBSTITUTION; HUMANS; KIDNEY NEOPLASMS; MOLECULAR TARGETED THERAPY; PROTEIN KINASE INHIBITORS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84942579594     PISSN: 09630643     EISSN: 14736586     Source Type: Journal    
DOI: 10.1097/MOU.0000000000000206     Document Type: Review

References (39)

1. Motzer RJ, Mazumdar M, Bacik J, et al. Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol 1999; 17:2530-2540.
2. Motzer RJ, Hutson TE, Tomczak P, et al. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol 2009; 27:3584-3590.
3. Oudard S, Elaidi RT. Sequential therapy with targeted agents in patients with advanced renal cell carcinoma: optimizing patient benefit. Cancer Treat Rev 2012; 38:981-987.
4. Hutson TE, Bukowski RM,Cowey CL, et al. Sequential use of targeted agents in the treatment of renal cell carcinoma. Crit RevOncolHematol 2011; 77:48-62.
5. Escudier B, Eisen T , Stadler WM, et al. Sorafenib in advanced clear-cell renalcell carcinoma. N Engl J Med 2007; 356:125-134.
6. Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007; 356:115-124.
7. Porta C, Tortora G, Linassier C, et al. Maximising the duration of disease control in metastatic renal cell carcinoma with targeted agents: an expert agreement. Med Oncol 2012; 29:1896-1907.
8. Bellmunt J, Pons F, Foreshew A, et al. Sequential targeted therapy after pazopanib therapy in patients with metastatic renal cell cancer: efficacy and toxicity. Clin Genitourin Cancer 2014; 12:262-269. Retrospective study of sequential-targeted therapy following first-line pazopanib in patients with mRCC.
9. Richter S, Seah JA, Pond GR, et al. Evaluation of second-line and subsequent targeted therapies in metastatic renal cell cancer (mRCC) patients treated with first-line cediranib. Can Urol Assoc J 2014; 8:398-402. Retrospective study of sequential-targ eted therapy following first-line cediranib in patients with mRCC.
10. Motzer RJ, Porta C, Vogelzang NJ, et al. Dovitinib versus sorafenib for thirdline targeted treatment of patients with metastatic renal cell carcinoma: an open-label, randomised phase 3 trial. Lancet Oncol 2014; 15:286-296. Phase 3 clinical trial comparing third-line therapy with dovitinib and sorafenib in patients with mRCC showing no significant difference between therapies.
11. Escudier B, Porta C, Schmidinger M, et al. Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2014; 25 (Suppl 3):iii49-iii56. Recent clinical practice gu idelines from ESMO for the management of mRCC.
12. Ljungberg B, Bensalah K, Canfield S, et al. EAU Guidelines on Renal Cell Carcinoma: 2014 Update. Eur Urol 2015. [Epub ahead of print] Recent clinical practice g uidelines from the EAU for the management of mRCC.
13. National Comprehensive Cancer Network (NCCN). NCCN clinical practice guidelines in Oncology. Kidney Cancer. Version 3. 2015. Available at: http://www.nccn .org/professionals/physician-gls/pdf/kidney.pdf [Accessed March 2015]. Recent update to the NCCN guidelines for the management of RCC. 14.
14. Porta C, Paglino C, Grunwald V. Sunitinib re-challenge in advanced renal-cell carcinoma. Br J Cancer 2014; 111:1047-1053. Systematic review and meta-Analyses of retropective studies and case reports of sunitinib rechallenge in mRCC demonstrating clinical benefits with rechallenge.
15. Hutson TE, Escudier B, Esteban E, et al. Randomized phase III trial of temsirolimus versus sorafenib as second-line therapy after sunitinib in patients with metastatic renal cell carcinoma. J Clin Oncol 2014; 32:760-767. Ph ase 3 trial demonstrating survival benefits with second-line TKIs versus mTOR inhibitors after first-line sunitinib.
16. Rini BI, Escudier B, Tomczak P, et al. Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. Lancet 2011; 378:1931-1939.
17. Escudier B, Michaelson MD, Motzer RJ, et al. Axitinib versus sorafenib in advanced renal c ell carcinoma: subanalyses by prior therapy from a randomised phase III trial. Br J Cancer 2014; 110:2821-2828. Subanalyses of a phase 3 trial comparing second-line axitinib and sorafenib demonstrating that a longer duration of the fir st-line therapy generally yields better outcome with the second-line therapy in mRCC.
18. Heng DY, Signorovitch J, Swallow E, et al. Comparative Effectiveness of Second-Line Targeted Therapies for Metastatic Renal Cell Carcinoma: A systematic review and meta-Analysis of real-world observational studies. PLoS One 2014; 9:e114264. Sytematic review of observational studies of second-line therapies for mRCC demonstrating a potential survival benefit with second-line mTOR inhibitors compared with VEGFR-TKIs in a subset of studies
19. Elaidi R,Har baoui A,Beuselinck B,et al. Outcomes from second-line therapy in long-term responders to first-line tyrosine kinase inhibitor in clear-cell metastatic renal cell carcinoma. Ann Oncol 2015 26 378-385. Retrospective multicenter ana lysis demonstrating that mRCCpatients who remain on first-line TKI for longer experience clinical benefit with TKI rechallenge rather than second-line mTOR inhibitors.
20. Joosten SC, Hamming L, Soetekouw PM, et al. Resis tance to sunitinib in renal cell carcinoma: From molecular mechanisms to predictive markers and future perspectives. Biochim Biophys Acta 2015; 1855:1-16. Review providing insights on the mechanisms of resistance to first-line targeted therapie s.
21. Hammers HJ, Verheul HM, Salumbides B, et al. Reversible epithelial to mesenchymal transition and acquired resistance to sunitinib in patients with renal cell carcinoma: evidence from a xenograft study. Mol Cancer Th er 2010; 9:1525-1535.
22. Beuselinck B, Job S, Becht E, et al. Molecular subtypes of clear cell renal cell carcinoma are associated with sunitinib response in the metastatic setting. Clin Cancer Res 2015; 21:1329-1339.
23. Giraldo N, Becht E, Pages F, et al. Orchestration and prognostic significance of immune checkpoints in the microenvironment of primary and metastatic renal cel l cancer. Clin Cancer Res 2015. [Epub ahead of print] Study examining the link between the tumor microenviroment and disease progression in mRCC.
24. Oudard S, Kramer G, Caffo O, et al. Docetaxel rechallenge after an initial good response in patients with metastatic castration-resistant prostate cancer. BJU Int 2014. [Epub ahead of print] Study highlighting the potential of chemotherapy rechallenge in castration resistant prostate cancer.
25. . Toulmonde M, Madranges N, Brouste V, et al. Docetaxel rechallenge after a first response in nonresistant metastatic breast cancer: significant activity with manageable toxicity. Breast Cancer Res Treat 2012; 134:325-332.
26. Gradishar WJ. Taxanes for the treatment of metastatic breast cancer. Breast Cancer (Auckl) 2012; 6:159-171.
27. Harries M, Gore M. Part II: chemotherapy for epithelial ovarian cancertreatment of recurrent disease. Lancet Oncol 2002; 3:537-545.
28. Huisman C, Postmus PE, Giaccone G, et al. Second-line chemotherapy and its evaluation in small cell lung cancer. Cancer Treat Rev 1999; 25:199-206.
29. Hainsworth JD, Rubin MS, Arrowsmith ER, et al. Pazopanib as second-line treatment after sunitinib or bevacizumab in patients with advanced renal c ell carcinoma: a Sarah Cannon Oncology Research Consortium Phase II Trial. Clin Genitourin Cancer 2013; 11:270-275.
30. Motzer RJ,Escudier B,Tomczak P,et al. Axitinib versus sorafenib as seco ndline treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial Lancet Oncol 2013 14 552-562.
31. Maj-Hes A, Medioni J, Scotte F, et al. Rechallenge with mTOR inhibitors in metastatic renal cell carcinoma patients who progressed on previous mTOR inhibitor therapy. Oncology 2013; 85:8-13.
32. Nozawa M, Yamamoto Y, Minami T, et al. Sorafenib rechallenge in patients with metastatic renal cell carcinoma. BJU Int 2012; 110:E228-E234.
33. Zama IN, Hutson TE, Elson P, et al. Sunitinib rechallenge in metastatic renal cell carcinoma patients. Cancer 2010; 116:5400-5406.
34. Grunwald V, Weikert S, Seidel C, et al. Efficacy of sunitinib re-exposure after failure of an mTOR inhibitor in patients with metastatic RCC.Onkologie 2011; 34:310-314.
35. Nagyivanyi K, Biro K, Gyergyay F, et al. Sunitinib rechallange in metastatic renal cell carcinoma patients. Ann Oncol 2012; 23:; Abstract 849P.
36. Shablak A, O'Dwyer J, Hawkins R, et al. Management of a new isolated metastasis during sunitinib treatment in renal cell carcinoma patients: a lesson fro m two cases. Urol Int 2011; 86:245-248.
37. Paule B, Brion N. Sunitinib re-challenge in metastatic renal cell carcinoma treated sequentially with tyrosine kinase inhibitors and everolimus. Anticancer Res 2011; 31:3507-3510.
38. Oudard S, Goupil MG, Geoffrois L, et al. Clinical activity of sunitinib rechallenge in metastatic renal cell carcinoma (mRCC)-Results of the RESUME study (Poster 816PD). Ann Oncol 2014; 25:iv283-iv284. The first study to include a prospective component of rechallenge with the same TKI in mRCC, demonstrating the clinical benefits of rechallenge.
39. Ko JJ, Choueiri TK, Rini BI, et al. First-, second-, third-line therapy for mRCC: benchmarks for trial design from the IMDC. Br J Cancer 2014; 110:1917-1922.